Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 84 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Insulin Low Dose Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Low-Dose Baclofen Administration on the GH-IGF1 Axis Study

NCT00871455
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Baclofen
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2012 · Synced Sep 3, 2026, 4:19 PM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

NCT07494084
View directory record Official record
Conditions
Shift Work Schedule, Circadian Rhythm, Insulin Resistance, Circadian Misalignment
Interventions
Metyrapone And Hydrocortisone, Dextrose, insulin
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessment of Mechanisms of Improved Wound Healing

NCT00673309
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion study, Insulin High Dose, oxandrolone, Propranolol, Growth Hormone, Insulin Low Dose, IGF-1/IGFBP-3, Itraconazole, Growth Hormone and Propranolol, Oxandrolone and Propranolol, Placebo or Control
Procedure · Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 90 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Omega-3 Fatty Acids on Markers of Inflammation

NCT01129050
View directory record Official record
Conditions
Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions
Fish Oil, Flaxseed Oil, Placebo
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 4 Interventional Results available

Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs

NCT02515773
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Metformin, healthy lifestyle intervention (LIFE)
Drug · Behavioral
Lead sponsor
Melissa Delbello
Other
Eligibility
8 Years to 19 Years
Enrollment
1,565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
29
States / cities
Covington, Kentucky • Neptune City, New Jersey • Amityville, New York + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 3, 2026, 4:19 PM EDT
Withdrawn Not applicable Interventional

Low Dose Growth Hormone Treatment in Subjects With Metabolic Syndrome.

NCT00720616
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Norditropin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 3, 2026, 4:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Measurement of Insulin Levels in Cerebral Spinal Fluid (CSF) of Healthy Adults After a Single Intranasal Dose

NCT05866367
View directory record Official record
Conditions
Healthy
Interventions
Low dose Regular Insulin, High dose Regular insulin
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Not applicable Interventional

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes

NCT03890003
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
AID System, Insulin Lispro
Device · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 3, 2026, 4:19 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 2 Interventional

Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents

NCT02714972
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia, Hyperglycemia, Artificial Pancreas
Interventions
Hyperglycemia Minimization Algorithm
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years to 14 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Stanford, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 3 Interventional Results available

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

NCT02580591
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
977 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
39
States / cities
Montgomery, Alabama • Concord, California • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 3, 2026, 4:19 PM EDT
Active, not recruiting Not applicable Interventional

Insulin Detemir in Obesity Management

NCT01239550
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Detemir
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
31 Years to 60 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Not applicable Interventional Results available

Dexcom Continuous Glucose Monitoring in Long-term Care

NCT04818242
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Dexcom G6 CGM with GTS, POC Blood Glucose Test + Blinded CGM
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Results available

Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth

NCT02168660
View directory record Official record
Conditions
Obesity, Insulin Resistance, Vitamin D Deficiency
Interventions
Vitamin D3
Drug
Lead sponsor
Perrin C White, MD
Other
Eligibility
6 Years to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Hi-maize Resistant Starch on Insulin Sensitivity

NCT01058135
View directory record Official record
Conditions
Insulin Resistance
Interventions
Hi-maize starch (Low dose), Hi-maize starch (High-dose), Control (starch)
Other
Lead sponsor
Ingredion Incorporated
Industry
Eligibility
18 Years to 69 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glen Ellyn, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia

NCT01919385
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Predictive Low Glucose Minimizer
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in Obese Adolescents

NCT00858247
View directory record Official record
Conditions
Obesity
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 3, 2026, 4:19 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age

NCT06434038
View directory record Official record
Conditions
Healthy
Interventions
Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
36 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Not applicable Interventional

Resveratrol-Leucine Metabolite Synergy in Pre-diabetes

NCT01593605
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Resveratrol, resveratrol /HMB, Placebo treatment
Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Metformin to Augment Low Milk Supply (MALMS) Study

NCT02179788
View directory record Official record
Conditions
Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions
Standard care, Metformin, Placebo
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
20 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 3, 2026, 4:19 PM EDT
Not listed No phase listed Observational

A Five-Year Quality of Life Study for Cancer Patients

NCT01539148
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Constantine A. Kotsanis
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Grapevine, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Phase 4 Interventional Results available

Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes

NCT02455076
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Glargine, Rapid-acting insulin analogs
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Sep 3, 2026, 4:19 PM EDT
Active, not recruiting Phase 2 Interventional

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

NCT05090358
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
Interventions
Ketogenic Diet, Low Carbohydrate Diet, Alpelisib, Fulvestrant, Canagliflozin
Dietary Supplement · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 3, 2026, 4:19 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Low Dose Fat-Induced Insulin Resistance

NCT03479671
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance, Insulin Sensitivity
Interventions
Intralipid, 20% Intravenous Emulsion
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 44 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 3, 2026, 4:19 PM EDT